CADTH | Evidence Driven
CADTH | Evidence Driven

Vismodegib (Erivedge) for Advanced BCC - Details

Details

Files
Generic Name:
Vismodegib
Project Status:
Complete
Therapeutic Area:
Basal Cell Carcinoma
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Erivedge
Project Line:
Reimbursement Review
Project Number:
PC0015-000
Strength:
150 mg capsule
Tumour Type:
Skin and Melanoma
Indications:
Advanced Basal Cell Carcinoma
Funding Request:
For the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma or with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary Provincial Funding Summary View PDF
Vismodegib (Erivedge) for Advanced BCC - pERC Final Recommendation Final Recommendation January 10, 2014 View PDF
Vismodegib (Erivedge) for Advanced BCC - Final Clinical Guidance Report Guidance Reports January 10, 2014 View PDF
Vismodegib (Erivedge) for Advanced BCC - Final Economic Guidance Report Guidance Reports January 10, 2014 View PDF
Vismodegib (Erivedge) for Advanced BCC - pERC Initial Recommendation Initial Recommendation October 31, 2013 View PDF
Vismodegib (Erivedge) for Advanced BCC - PAG Feedback on Initial Recommendation Feedback January 10, 2014 View PDF
Vismodegib (Erivedge) for Advanced BCC - Manufacturer (Hoffmann-La Roche Ltd) Feedback on Initial Recommendation Feedback January 10, 2014 View PDF
Vismodegib (Erivedge) for Advanced BCC - Patient Advocacy Group (SYS) Feedback on Initial Recommendation Feedback January 10, 2014 View PDF
Vismodegib (Erivedge) for Advanced BCC - Patient Advocacy Group (SYS) COI Declarations Feedback January 10, 2014 View PDF
Vismodegib (Erivedge) for Advanced BCC - Patient Advocacy Group (MNC) COI Declarations Feedback January 10, 2014 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : January 27, 2014